Turquía

Artículos Recientes

•  

  25/04/2024

  Turquía

  Data protection reform in Türkiye: a step towards alignment with EU’s GDPR

  In a major step towards compliance with the EU's General Data Protection Regulation (GDPR), on February 16, 2024, lawmakers in Türkiye submitted a Law to the General Assembly of the Turkish Grand National Assembly (TGNA) as part of the 8th Legislative Package on long-awaited amendments to the Personal Data Protection Law No. 6698 (LPPD). The amendments were approved on March 1, 2024 by TGNA, and the Law was published in the Official Gazette on 12 March 2024 following confirmation by the President of the Republic of Türkiye.The most important changes in the Law, which significantly facilitate...

  Leer más
•  

  25/04/2024

  Europe

  Cheers! New EU rules to strengthen GI protection for wine, spirit drinks and agri-food products come into force on 13 May 2024

  On 23 April 2024, a new EU regulation aimed at enhancing the protection of geographical indications (GIs) for wine, spirit drinks and agricultural products, and other quality schemes for agricultural products was published in the Official Journal. The new rules, that enter into force on 13 May 2024, provide for a streamlined registration procedure, a strengthened role of producer groups, and improved provisions on GI protection (both online and offline) and sustainability.Background on Geographical Indications (GIs) for wine, spirit drinks and agri-food productsGIs are intellectual property rights...

  Leer más
•  

  25/04/2024

  Turquía

  Proposed EU Directive on Harmonisation of Insolvency Law could safeguard Turkish creditors, if adopted

  Insolvency proceedings and avoidance actions play a significant role in safeguarding creditors' interests and maximising the insolvency estate in Türkiye. The European Commission's Proposal for a Directive (COM (2022)702) aims to harmonise contestation rights in insolvency across EU member states. Although Türkiye is not an EU member states, Türkiye has similar avoidance actions regulated under its own insolvency legislation, the Turkish Enforcement and Bankruptcy Law (EBL).OverviewSimilar to the EU’s proposed Directive, the EBL contains provisions for the annulment of transaction...

  Leer más
•  

  18/04/2024

  International

  Transforming the Legal Landscape? The Impact of LLMs

  Large Language Models (LLMs) are a branch of artificial intelligence (AI) that can generate human-like text based on deep learning techniques. LLMs are trained on massive amounts of textual data, such as books, articles, and websites, and learn to recognise patterns, structures, and relationships within the data. By doing so, they develop the ability to produce text on various topics. The presence of LLMs in the legal sector is increasing and, with this, the ability of lawyers to understand and use LLMs in providing quality advice to their clients is becoming more important. CMS have a dedicated...

  Leer más
•  

  17/04/2024

  Europe

  CMS data protection update (04/2024)

  I. The latest from the data protection authorities and current topics1. EDPB: Launch of coordinated enforcement on the right of accessThe European Data Protection Board (EDPB) selected the right of access under Article 15 GDPR as the focus of the third coordinated enforcement action of the data protection authorities. Coordinated enforcement has now begun and aims to help assess how the right of access is implemented in practice and to what extent adjustments or clarifications are needed in the EDPB's Guidelines on this topic. Last year’s results of the coordinated enforcement action on the...

  Leer más
•  

  12/04/2024

  Europe

  Navigating clinical trial disclosures: No reasonable expectation of success in a patient sub-population in view of prior art reporting phase III clinical trial (T 1437/21)

  Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial. At a time when the European Medicines Agency (EMA) is requiring increased transparency for EU clinical trials, this case law is of increasing importance to those operating in the pharmaceutical space.In brief, this decision further supports the position that the disclosure of a clinical trial protocol does not always mean there is a reasonable expectation of success of achieving treatment. The...

  Leer más